Colorectal cancer chemoprevention--an overview of the science

Ernest T Hawk ¹, Asad Umar , Jaye L Viner

⁰Gastrointentinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute/NIH, EPN Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA. eh51p@nih.gov

Gastroenterology +

|

May 8, 2004

View abstract on PubMed

Summary

Sophisticated detection reveals widespread preinvasive colorectal neoplasia. Effective interventions are crucial for risk reduction, necessitating prioritized clinical testing of lead prevention compounds and innovative trial designs.

Area Of Science

Oncology
Preventive Medicine
Clinical Pharmacology

Background

Advanced detection technologies highlight a high prevalence of preinvasive colorectal neoplasia in U.S. adults.
Cancer screening and surveillance aid risk stratification but require effective interventions for risk reduction.

Purpose Of The Study

To review lead compounds for colorectal cancer prevention.
To outline measures for prioritizing these compounds for clinical testing.
To discuss the need for novel clinical trial designs in cancer prevention.

Main Methods

Literature review of lead compounds for colorectal cancer prevention.
Analysis of strategies for prioritizing compounds for clinical testing.
Exploration of innovative clinical trial designs.

Main Results

Identification of lead compounds for colorectal cancer prevention.
Discussion of prioritization metrics for clinical evaluation.
Highlighting clinical trials as a bottleneck in agent development.

Conclusions

Effective interventions are essential for colorectal cancer risk reduction.
Novel trial designs are critical to accelerate the identification and testing of preventive agents.
Innovative models, such as nesting prevention endpoints in treatment trials, can advance cancer prevention research.

Related Concept Videos